EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2808	514/456	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 13:21
L2	70	l1 and "prostate cancer".clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 14:34
L3	3338	"vitamin E".clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 14:34
L4	2350	"tocopherol".clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 14:34
L5	5224	l3 or l4	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 14:34
L6	46	l5 and "prostate cancer".clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 14:52
L7	14	l1 and "thompson".in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 14:53
L8	1	l1 and "wilding".in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/01/30 14:53

10/789,835
GENUS SEARCH

FILE 'HOME' ENTERED AT 11:59:27 ON 30 JAN 2007

=> **file registry**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:59:45 ON 30 JAN 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1
DICTIONARY FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10789835_genus.str





chain nodes :
11 12 13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
1-14 2-13 3-12 4-11 8-15 8-16 9-17 9-18 10-19 10-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :

1-14 2-13 3-12 4-11 5-7 6-10 7-8 8-9 8-15 8-16 9-10 9-17 9-18 10-19
10-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1 CH3,Et,n-Pr,i-Pr NO H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> **d l1**
L1 HAS NO ANSWERS
L1 STR



G1 Me,Et,n-Pr,i-Pr

Structure attributes must be viewed using STN Express query preparation.

=> **s l1**
SAMPLE SEARCH INITIATED 12:00:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3625 TO ITERATE

55.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 68889 TO 76111
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> **s l1 full**
FULL SEARCH INITIATED 12:00:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 72298 TO ITERATE

100.0% PROCESSED 72298 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> **s l1 sss full**
FULL SEARCH INITIATED 12:03:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 72298 TO ITERATE

100.0% PROCESSED 72298 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10789835_genus2.str





chain nodes :
11 12 13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
1-14 2-13 3-12 4-11 8-15 8-16 9-17 9-18 10-19 10-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
1-14 2-13 3-12 4-11 5-7 6-10 7-8 8-9 8-15 8-16 9-10 9-17 9-18 10-19
10-20
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:CH3,Et,n-Pr,i-Pr,H ALLOW FOR H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L5 STRUCTURE UPLOADED

=> **d 15**
L5 HAS NO ANSWERS
L5 STR



G1 Me,Et,n-Pr,i-Pr,H

Structure attributes must be viewed using STN Express query preparation.

=> **s 15 full**
FULL SEARCH INITIATED 12:06:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 639558 TO ITERATE

100.0% PROCESSED 639558 ITERATIONS 900 ANSWERS
SEARCH TIME: 00.00.03

L6 900 SEA SSS FUL L5

=> **file medline, caplus, wpids, uspatfull**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	520.35	520.56

FILE 'MEDLINE' ENTERED AT 12:06:59 ON 30 JAN 2007

FILE 'CAPLUS' ENTERED AT 12:06:59 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'WPIDS' ENTERED AT 12:06:59 ON 30 JAN 2007

FILE 'USPATFULL' ENTERED AT 12:06:59 ON 30 JAN 2007

=> **s 16**
SAMPLE SEARCH INITIATED 12:07:06 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 1870 TO ITERATE

53.5% PROCESSED 1000 ITERATIONS 5 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 17416 TO 19984
PROJECTED ANSWERS: 5 TO 184

L7 1190 L6

=> **s l7 not py>2004**
L8 1040 L7 NOT PY>2004

=> **s l8 and "prostate cancer"**
2 FILES SEARCHED...
L9 16 L8 AND "PROSTATE CANCER"

=> **s l8 and "androgen"**
L10 12 L8 AND "ANDROGEN"

=> **d l10 1-12 ibib, abs, hitstr**

L10 ANSWER 1 OF 12 MEDLINE on STN
ACCESSION NUMBER: 2003400986 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 12939470
TITLE: Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.
AUTHOR: Thompson Todd A; Wilding George
CORPORATE SOURCE: University of Wisconsin Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin 53792, USA.
SOURCE: Molecular cancer therapeutics, (2003 Aug) Vol. 2, No. 8, pp. 797-803.
Journal code: 101132535. ISSN: 1535-7163.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200406
ENTRY DATE: Entered STN: 27 Aug 2003
Last Updated on STN: 24 Jun 2004
Entered Medline: 21 Jun 2004

AB Antioxidants, such as vitamin E, are being investigated for efficacy in prostate cancer prevention. In this study, we show that the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol (PMCol), has antiandrogen activity in prostate carcinoma cells. In the presence of PMCol, the androgen-stimulated biphasic growth curve of LNCaP human prostate carcinoma cells was shifted to the right. The PMCol-induced growth shift was similar to that produced by treatment with the pure antiandrogen bicalutamide (i.e., Casodex), indicative of androgen receptor (AR) antagonist activity. The concentration of PMCol used was below the concentration required to affect cell growth or viability in the absence of androgen. Using an AR binding competition assay, PMCol was found to be a potent antiandrogen in both LNCaP and LAPC4 cells, with an IC(50) of approximately 10 micro M against 1 nM R1881 (methyltrienolone; a stable, synthetic androgen). Prostate-specific antigen release from LNCaP cells produced by androgen exposure with either 0.05 or 1.0 nM R1881 was inhibited 100% and 80%, respectively, by 30 micro M PMCol. Also, PMCol inhibited androgen-induced promoter activation in both LNCaP and LAPC4 cells. However, PMCol did not affect AR protein levels, suggesting that the

inhibitory effects of PMCol on androgenic pathways were not due to decreased expression of the AR. Therefore, growth modulation by the antioxidant moiety of vitamin E in androgen-sensitive prostate carcinoma cells is due, at least in part, to its potent antiandrogenic activity.

L10 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:665773 CAPLUS Full-text
DOCUMENT NUMBER: 140:52950
TITLE: Androgen Antagonist Activity by the Antioxidant Moiety of Vitamin E, 2,2,5,7,8-Pentamethyl-6-chromanol in Human Prostate Carcinoma Cells
AUTHOR(S): Thompson, Todd A.; Wilding, George
CORPORATE SOURCE: University of Wisconsin Comprehensive Cancer Center and University of Wisconsin Department of Medicine, University of Wisconsin-Madison, Madison, WI, 53792, USA
SOURCE: Molecular Cancer Therapeutics (2003), 2(8), 797-803
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Antioxidants, such as vitamin E, are being investigated for efficacy in prostate cancer prevention. In this study, we show that the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol (PMCol), has antiandrogen activity in prostate carcinoma cells. In the presence of PMCol, the androgen-stimulated biphasic growth curve of LNCaP human prostate carcinoma cells was shifted to the right. The PMCol-induced growth shift was similar to that produced by treatment with the pure antiandrogen bicalutamide (i.e., Casodex), indicative of androgen receptor (AR) antagonist activity. The concentration of PMCol used was below the concentration required to affect cell growth or viability in the absence of androgen. Using an AR binding competition assay, PMCol was found to be a potent antiandrogen in both LNCaP and LAPC4 cells, with an IC50 of approx. 10 μM against 1 nM R1881 (methyltrienolone; a stable, synthetic androgen). Prostate-specific antigen release from LNCaP cells produced by androgen exposure with either 0.05 or 1.0 nM R1881 was inhibited 100% and 80%, resp., by 30 μM PMCol. Also, PMCol inhibited androgen-induced promoter activation in both LNCaP and LAPC4 cells. However, PMCol did not affect AR protein levels, suggesting that the inhibitory effects of PMCol on androgenic pathways were not due to decreased expression of the AR. Therefore, growth modulation by the antioxidant moiety of vitamin E in androgen-sensitive prostate carcinoma cells is due, at least in part, to its potent antiandrogenic activity.
IT 950-99-2, 2,2,5,7,8-Pentamethyl-6-chromanol
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells)
RN 950-99-2 CAPLUS
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:315490 USPATFULL Full-text
TITLE: Substituted benzopyrans as selective estrogen receptor-beta agonists
INVENTOR(S): Dodge, Jeffrey Alan, Indianapolis, IN, UNITED STATES
Krishnan, Venkatesh, Fishers, IN, UNITED STATES
Lugar, Charles Willis, McCordsville, IN, UNITED STATES
Neubauer, Blake Lee, Carmel, IN, UNITED STATES
Norman, Bryan Hurst, Indianapolis, IN, UNITED STATES
Pfeifer, Lance Allen, Indianapolis, IN, UNITED STATES
Richardson, Timothy Ivo, Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004249167	A1	20041209	
APPLICATION INFO.:	US 2004-493092	A1	20040420	(10)
	WO 2002-US33622		20021107	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60332766	20011119
	US 2002-60363622	20020311

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael J Sayles, Eli Lilly & Company, Patent Division, PO Box 6288, Indianapolis, IN, 46206-6288
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 2943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor β agonists. Such agonists are useful for the treating Estrogen Receptor β mediated diseases such as prostate cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 533883-77-1P 533883-83-9P 533883-84-0P
533883-86-2P 533883-87-3P 533883-89-5P
533883-90-8P 533883-91-9P 533883-92-0P
533883-95-3P 533883-96-4P 533883-97-5P
533884-02-5P 533884-04-7P 533884-08-1P
533884-09-2P 533884-10-5P 533884-16-1P
533884-17-2P 533884-19-4P 533884-20-7P
533884-22-9P 533884-23-0P 533884-25-2P

533884-26-3P 533884-29-6P 533884-31-0P
(drug candidate; preparation of benzopyran derivs. as selective estrogen receptor β agonists)

RN 533883-77-1 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-83-9 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-6-methyl-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-84-0 USPATFULL
CN Benzo[b]cyclohepta[d]pyran-2-ol, 6,6a,7,8,9,10,11,11a-octahydro-6-(4-hydroxyphenyl)-, (6R,6aS,11aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-86-2 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-1,1-dimethyl-, (3aR,4S,9bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-87-3 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,1-diethyl-1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4S,9bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-89-5 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxy-3-methylphenyl)-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-90-8 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxy-3-methylphenyl)-, (3aR,4R,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-91-9 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxy-2-methylphenyl)-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-92-0 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4R,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-95-3 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-7-methyl-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-96-4 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-7-methyl-, (3aR,4R,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533883-97-5 USPATFULL
CN 6H-Dibenzo[b,d]pyran-2-ol, 6a,7,8,9,10,10a-hexahydro-6-(4-hydroxyphenyl)-, (6R,6aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533884-02-5 USPATFULL
CN Benzamide, 4-[(3aR,4S,9bS)-1,2,3,3a,4,9b-hexahydro-8-hydroxycyclopenta[c][1]benzopyran-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533884-04-7 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-methoxyphenyl)-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533884-08-1 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4S,9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 533884-09-2 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aS,4R,9bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 533884-10-5 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 533884-16-1 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 533884-17-2 USPATFULL
CN Benzo[b]cyclohepta[d]pyran-2-ol, 6,6a,7,8,9,10,11,11a-octahydro-6-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 533884-19-4 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-1,1-dimethyl- (9CI) (CA INDEX NAME)



RN 533884-20-7 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,1-diethyl-1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 533884-22-9 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxy-3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 533884-23-0 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxy-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 533884-25-2 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)



RN 533884-26-3 USPATFULL
CN 6H-Dibenzo[b,d]pyran-2-ol, 6a,7,8,9,10,10a-hexahydro-6-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 533884-29-6 USPATFULL
CN Benzamide, 4-(1,2,3,3a,4,9b-hexahydro-8-hydroxycyclopenta[c][1]benzopyran-4-yl)- (9CI) (CA INDEX NAME)



RN 533884-31-0 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT 533885-01-7P 533885-03-9P
(intermediate; preparation of benzopyran derivs. as selective estrogen receptor β agonists)

RN 533885-01-7 USPATFULL

CN Methanesulfonic acid, trifluoro-, 4-[(3aR,4S,9bS)-1,2,3,3a,4,9b-hexahydro-8-hydroxycyclopenta[c][1]benzopyran-4-yl]phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 533885-03-9 USPATFULL

CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-[4-(phenylmethoxy)phenyl]-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 4 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2004:300069 USPATFULL Full-text
TITLE:	Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
INVENTOR(S):	Sanders, Bob G., Austin, TX, UNITED STATES Kline, Kimberly, Austin, TX, UNITED STATES Hurley, Laurence, Austin, TX, UNITED STATES Gardner, Robb, Austin, TX, UNITED STATES Menchaca, Marla, Austin, TX, UNITED STATES Yu, Weiping, Austin, TX, UNITED STATES Ramanan, Puthucode N., Austin, TX, UNITED STATES Liu, Shenquan, Austin, TX, UNITED STATES Israel, Karen, Austin, TX, UNITED STATES
PATENT ASSIGNEE(S):	Research Development Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004235938	A1	20041125
APPLICATION INFO.:	US 2003-644418	A1	20030820 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-502592, filed on 11 Feb 2000, GRANTED, Pat. No. US 6770672 Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, GRANTED, Pat. No. US 6417223

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071
NUMBER OF CLAIMS:	30
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	21 Drawing Page(s)
LINE COUNT:	2556

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 950-99-2
(preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for use as antitumor agents and for inducing cell apoptosis)
RN 950-99-2 USPATFULL
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2004:192666 USPATFULL Full-text
TITLE:	Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
INVENTOR(S):	Sanders, Bob G., Austin, TX, United States Kline, Kimberly, Austin, TX, United States Hurley, Laurence, Austin, TX, United States Gardner, Robb, Austin, TX, United States Menchaca, Marla, Austin, TX, United States Yu, Weiping, Austin, TX, United States Ramanan, Puthucode N., Austin, TX, United States Liu, Shenquan, Austin, TX, United States Israel, Karen, Austin, TX, United States
PATENT ASSIGNEE(S):	Research Development Foundation, Carson City, NV, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6770672	B1	20040803
APPLICATION INFO.:	US 2000-502592		20000211 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, now patented, Pat. No. US 6417223, issued on 9 Jul 2002		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101543P	19980923 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Fonda, Kathleen K.
ASSISTANT EXAMINER:	Maier, Leigh C.
LEGAL REPRESENTATIVE:	Adler, Benjamin Aaron
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 18 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 2359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 950-99-2, 2,2,5,7,8-Pentamethyl-6-chromanol
(preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for therapeutic use in prevention and treatment of cancer)
RN 950-99-2 USPATFULL
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:127448 USPATFULL Full-text
TITLE: Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
INVENTOR(S): Sanders, Bob G., Austin, TX, UNITED STATES
Kline, Kimberly, Austin, TX, UNITED STATES
Yu, Weiping, Austin, TX, UNITED STATES
PATENT ASSIGNEE(S): Research Development Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097431	A1	20040520
APPLICATION INFO.:	US 2003-695275	A1	20031028 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-8066, filed on 5 Nov 2001, GRANTED, Pat. No. US 6703384 Continuation-in-part of Ser. No. US 2000-502592, filed on 11 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, GRANTED, Pat. No. US 6417223

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Benjamin Aaron Adler, Ph.D., J.D., Adler & Associates, 8011 Candle Lane, Houston, TX, 77071
NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 2605
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an antiproliferative compound having a structural formula ##STR1##

where X and Y independently are oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitrites; R.sup.2 and R.sup.3 are hydrogen or R.sup.4; R.sup.4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R.sup.5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R.sup.6, wherein R.sup.6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 950-99-2
(preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for use as antitumor agents and for inducing cell apoptosis)
RN 950-99-2 USPATFULL
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 7 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2003:268231 USPATFULL Full-text
TITLE: Substituted benzopyrans as selective estrogen receptor β agonists
INVENTOR(S): Dodge, Jeffrey Alan, Indianapolis, IN, United States
Krishnan, Venkatesh, Fishers, IN, United States
Lugar, III, Charles Willis, McCordsville, IN, United States
Neubauer, Blake Lee, Carmel, IN, United States
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6630508	B1	20031007	
APPLICATION INFO.:	US 2003-349521		20030122	(10)

	NUMBER	DATE

PRIORITY INFORMATION: US 2002-355891P 20020211 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Aulakh, Charanjit S.
LEGAL REPRESENTATIVE: Sayles, Michael J.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor β agonists. Such agonists are useful for treating Estrogen Receptor β mediated diseases such as prostate cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 609806-61-3P 609806-62-4P 609806-63-5P
609806-64-6P 609806-65-7P 609806-66-8P
(preparation of arylcyclopentabenzopyrans and related compds. as selective estrogen receptor β agonists)

RN 609806-61-3 USPATFULL

CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-phenyl-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 609806-62-4 USPATFULL

CN Cyclopenta[c][1]benzopyran-8-ol, 4-(4-fluorophenyl)-1,2,3,3a,4,9b-hexahydro-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 609806-63-5 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 4-(4-ethylphenyl)-1,2,3,3a,4,9b-hexahydro-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 609806-64-6 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-[4-(trifluoromethyl)phenyl]-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 609806-65-7 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(3-hydroxyphenyl)-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 609806-66-8 USPATFULL
CN Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-methylphenyl)-, (3aR,4S,9bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 8 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2003:38151 USPATFULL Full-text
TITLE: Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
INVENTOR(S): Druzgala, Pascal, Santa Rosa, CA, UNITED STATES
Milner, Peter G., Los Altos Hills, CA, UNITED STATES
Pfister, Jurg R., Los Altos, CA, UNITED STATES

NUMBER	KIND	DATE

PATENT INFORMATION: US 2003027798 A1 20030206
US 6768008 B2 20040727
APPLICATION INFO.: US 2001-961542 A1 20010921 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-841351, filed on 24 Apr 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-199146P	20000424 (60)
	US 2000-234423P	20000921 (60)
	US 2001-281982P	20010406 (60)
	US 2001-314792P	20010824 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Page(s)
LINE COUNT: 2393
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 494870-56-3P 494870-57-4P 494870-58-5P
494870-59-6P
(preparation of benzylazolidinediones for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis)

RN 494870-56-3 USPATFULL

CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-5,7,8-trimethyl-, 4-[(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 494870-57-4 USPATFULL
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-5,7,8-trimethyl-, 4-[(2,4-dioxo-5-thiazolidinylidene)methyl]phenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 494870-58-5 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[[(2R)-3,4-dihydro-6-hydroxy-5,7,8-trimethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 494870-59-6 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[[(2S)-3,4-dihydro-6-hydroxy-5,7,8-trimethyl-2H-1-benzopyran-2-yl]methoxy]phenyl]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L10 ANSWER 9 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2002:280579 USPATFULL Full-text
TITLE: Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
INVENTOR(S): Sanders, Bob G., Austin, TX, UNITED STATES
Kline, Kimberly, Austin, TX, UNITED STATES
Hurley, Laurence, Austin, TX, UNITED STATES
Gardner, Robb, Austin, TX, UNITED STATES
Menchaca, Marla, Austin, TX, UNITED STATES
Yu, Weiping, Austin, TX, UNITED STATES
Ramanan, Puthucode N., Austin, TX, UNITED STATES
Liu, Shenquan, Austin, TX, UNITED STATES
Israel, Karen, Austin, TX, UNITED STATES
PATENT ASSIGNEE(S): Research Development Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002156024	A1	20021024
	US 6645998	B2	20031111
APPLICATION INFO.:	US 2002-122019	A1	20020412 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-404001, filed on 23 Sep 1999, GRANTED, Pat. No. US 6417223

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers and nitriles; R.sup.2 is hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.3 is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.4 is of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; and R.sup.5 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 950-99-2
(preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for use as antitumor agents and for inducing cell apoptosis)
RN 950-99-2 USPATFULL

CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER:	2002:199098 USPATFULL Full-text		
TITLE:	Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof		
INVENTOR(S):	Sanders, Bob G., Austin, TX, UNITED STATES Kline, Kimberly, Austin, TX, UNITED STATES Yu, Weiping, Austin, TX, UNITED STATES		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107207	A1	20020808
	US 6703384	B2	20040309
APPLICATION INFO.:	US 2001-8066	A1	20011105 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-502592, filed on 11 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, PENDING		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	2606		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an antiproliferative compound having a structural formula ##STR1##

where X and Y independently are oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitrites; R.sup.2 and R.sup.3 are hydrogen or R.sup.4; R.sup.4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R.sup.5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R.sup.6, wherein R.sup.6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 950-99-2, 2,2,5,7,8-Pentamethyl-6-chromanol
(preparation of tocopherols, tocotrienols, other chromans and side chain derivs. as potential antiproliferative, proapoptotic agents for the treatment of cancer)
RN 950-99-2 USPATFULL
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 11 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2002:168253 USPATFULL Full-text
TITLE: Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof
INVENTOR(S): Sanders, Bob G., Austin, TX, United States
Kline, Kimberly, Austin, TX, United States
Hurley, Laurence, Austin, TX, United States
Gardner, Robb, Austin, TX, United States
Menchaca, Marla, Austin, TX, United States
Yu, Weiping, Austin, TX, United States
Ramanan, Puthucode N., Austin, TX, United States
Liu, Shenquan, Austin, TX, United States
Israel, Karen, Austin, TX, United States
PATENT ASSIGNEE(S): Research Development Foundation, Carson City, NV, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6417223	B1	20020709	
APPLICATION INFO.:	US 1999-404001		19990923	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Wilson, James O.
ASSISTANT EXAMINER: Maier, Leigh C.
LEGAL REPRESENTATIVE: Adler, Benjamin Aaron
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester,

thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers and nitriles; R.sup.2 is hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.3 is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.4 is of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; and R.sup.5 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 950-99-2
(preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for use as antitumor agents and for inducing cell apoptosis)
RN 950-99-2 USPATFULL
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 12 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2001:22257 USPATFULL Full-text
TITLE: Methods for treating benign prostatic hyperplasia using tocotrienols
INVENTOR(S): Lane, Ronald H., Phoenix, AZ, United States
PATENT ASSIGNEE(S): LipoGenics, Inc., Phoenix, AZ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6187811	B1	20010213	
APPLICATION INFO.:	US 1998-182115		19981028	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Witz, Jean C.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the treatment of benign prostatic hyperplasia (BPH) using tocotrienols. Specifically, this invention relates to compositions and the use of compositions comprising individual tocotrienols, mixtures of tocotrienols and mixtures of one or more tocotrienols with other anti-BPH substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 150035-60-2
(oral compns. containing tocotrienols and addnl. active agents for treatment of benign prostatic hyperplasia)
RN 150035-60-2 USPATFULL
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2-[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> **d his**

(FILE 'HOME' ENTERED AT 11:59:27 ON 30 JAN 2007)

FILE 'REGISTRY' ENTERED AT 11:59:45 ON 30 JAN 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FULL
L4 0 S L1 SSS FULL
L5 STRUCTURE UPLOADED
L6 900 S L5 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:06:59 ON 30 JAN 2007
L7 1190 S L6
L8 1040 S L7 NOT PY>2004
L9 16 S L8 AND "PROSTATE CANCER"
L10 12 S L8 AND "ANDROGEN"

=> **d 19 1-16 ibib, abs, histr**
'HISTR' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ibib, abs

L9 ANSWER 1 OF 16 MEDLINE on STN
ACCESSION NUMBER: 2003400986 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 12939470
TITLE: Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.
AUTHOR: Thompson Todd A; Wilding George
CORPORATE SOURCE: University of Wisconsin Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin 53792, USA.
SOURCE: Molecular cancer therapeutics, (2003 Aug) Vol. 2, No. 8, pp. 797-803.
Journal code: 101132535. ISSN: 1535-7163.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English

FILE SEGMENT: Priority Journals
ENTRY MONTH: 200406
ENTRY DATE: Entered STN: 27 Aug 2003
Last Updated on STN: 24 Jun 2004
Entered Medline: 21 Jun 2004

AB Antioxidants, such as vitamin E, are being investigated for efficacy in prostate cancer prevention. In this study, we show that the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol (PMCol), has antiandrogen activity in prostate carcinoma cells. In the presence of PMCol, the androgen-stimulated biphasic growth curve of LNCaP human prostate carcinoma cells was shifted to the right. The PMCol-induced growth shift was similar to that produced by treatment with the pure antiandrogen bicalutamide (i.e., Casodex), indicative of androgen receptor (AR) antagonist activity. The concentration of PMCol used was below the concentration required to affect cell growth or viability in the absence of androgen. Using an AR binding competition assay, PMCol was found to be a potent antiandrogen in both LNCaP and LAPC4 cells, with an IC(50) of approximately 10 micro M against 1 nM R1881 (methyltrienolone; a stable, synthetic androgen). Prostate-specific antigen release from LNCaP cells produced by androgen exposure with either 0.05 or 1.0 nM R1881 was inhibited 100% and 80%, respectively, by 30 micro M PMCol. Also, PMCol inhibited androgen-induced promoter activation in both LNCaP and LAPC4 cells. However, PMCol did not affect AR protein levels, suggesting that the inhibitory effects of PMCol on androgenic pathways were not due to decreased expression of the AR. Therefore, growth modulation by the antioxidant moiety of vitamin E in androgen-sensitive prostate carcinoma cells is due, at least in part, to its potent antiandrogenic activity.

L9 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:784630 CAPLUS Full-text
DOCUMENT NUMBER: 139:292149
TITLE: Preparation of arylcyclopentabenzopyrans and related compounds as selective estrogen receptor β agonists
INVENTOR(S): Dodge, Jeffrey Alan; Krishnan, Venkatesh; Lugar, Charles Willis, III; Neubauer, Blake Lee
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: U.S., 20 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6630508	B1	20031007	US 2003-349521		20030122
PRIORITY APPLN. INFO.:			US 2002-355891P	P	20020211

OTHER SOURCE(S): MARPAT 139:292149
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. (I; R1, R2 = H, alkyl, OH, alkoxy, halo, CF3; R3 = H, alkyl, halo, CF3; Y1, Y2, Y3 = H, alkyl; G = CH2, CH2CH2, CH2CH2CH2; with the proviso that when G = CH2 and R1, R2, R3, Y2, and Y3 all = H, then Y1 cannot = Me), were prepared Thus, intermediate (II) in MeOH was heated at 50° with 4-

MeC6H4SO3H for 18 h; to the mixture at ambient temperature was added bromocreosol green and NaBH3CN. MeOH saturated with HCl was added portionwise over time to maintain the yellow color to give 72% 2-(4-methylphenyl)-6-hydroxycyclopenta[c]3,4-dihydro-2H-1-benzopyran (III). III in an estrogen receptor (ER) binding assay showed a ratio of ERα/ERβ Ki's of 12.6.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:719298 CAPLUS Full-text

DOCUMENT NUMBER: 139:245900

TITLE: Preparation of substituted benzopyrans as selective estrogen receptor β agonists

INVENTOR(S): Lugar, Charles Willis, III; Dodge, Jeffrey Alan; Krishnan, Venkatesh Gary; Neubauer, Blake Lee; Norman, Bryan Hurst

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003074044	A1	20030912	WO 2003-US2678		20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003212856	A1	20030916	AU 2003-212856		20030213
PRIORITY APPLN. INFO.:			US 2002-361524P	P	20020301
			WO 2003-US2678	W	20030213

OTHER SOURCE(S): MARPAT 139:245900

GI



I

AB Benzopyrans I [R1-R4 = H, alkyl, OH, alkoxy, Halogen, CF3; R5, R6 = H, alkyl] were prepared for use as selective estrogen receptor β agonists in treatment of diseases such as prostate cancer. Thus, MeCOCHMeCO2Et was converted to F3CSO2OCMe:CMeCO2Et which was treated with 2,5-(MeOCH2O)2C6H3Br to give 2,5-

(MeOCH2O)2C6H3CMe:CMeCO2Et. This compound was reduced stereoselectively to cis-2,5- (MeOCH2O)2C6H3CHMeCHMeCO2Et which was converted to cis-2,5-(MeOCH2O)2C6H3CHMeCHMeCONMeOMe and treated with 4-MeOCH2OC6H4Br to give cis-2,5-(MeOCH2O)2C6H3CHMeCHMeCOC6H4OCH2OMe-4. This compound was cyclized in presence of O and reduced with NaBH3CN to give 3,4-cis-I [R1 = 6-OH, R2, R3 = H, R4 = 4-OH, R5, R6 = Me, II] as a 6:1 cis-trans mixture at the 2-position. II had Ki(ERα)/Ki(ERβ) of 7.7.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:665773 CAPLUS Full-text

DOCUMENT NUMBER: 140:52950

TITLE: Androgen Antagonist Activity by the Antioxidant Moiety of Vitamin E, 2,2,5,7,8-Pentamethyl-6-chromanol in Human Prostate Carcinoma Cells

AUTHOR(S): Thompson, Todd A.; Wilding, George

CORPORATE SOURCE: University of Wisconsin Comprehensive Cancer Center and University of Wisconsin Department of Medicine, University of Wisconsin-Madison, Madison, WI, 53792, USA

SOURCE: Molecular Cancer Therapeutics (2003), 2(8), 797-803
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Antioxidants, such as vitamin E, are being investigated for efficacy in prostate cancer prevention. In this study, we show that the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol (PMCol), has antiandrogen activity in prostate carcinoma cells. In the presence of PMCol, the androgen-stimulated biphasic growth curve of LNCaP human prostate carcinoma cells was shifted to the right. The PMCol-induced growth shift was similar to that produced by treatment with the pure antiandrogen bicalutamide (i.e., Casodex), indicative of androgen receptor (AR) antagonist activity. The concentration of PMCol used was below the concentration required to affect cell growth or viability in the absence of androgen. Using an AR binding competition assay, PMCol was found to be a potent antiandrogen in both LNCaP and LAPC4 cells, with an IC50 of approx. 10 μM against 1 nM R1881 (methyltrienolone; a stable, synthetic androgen). Prostate-specific antigen release from LNCaP cells produced by androgen exposure with either 0.05 or 1.0 nM R1881 was inhibited 100% and 80%, resp., by 30 μM PMCol. Also, PMCol inhibited androgen-induced promoter activation in both LNCaP and LAPC4 cells. However, PMCol did not affect AR protein levels, suggesting that the inhibitory effects of PMCol on androgenic pathways were not due to decreased expression of the AR. Therefore, growth modulation by the antioxidant moiety of vitamin E in androgen-sensitive prostate carcinoma cells is due, at least in part, to its potent antiandrogenic activity.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 16 USPATFULL on STN

ACCESSION NUMBER: 2004:315490 USPATFULL Full-text

TITLE: Substituted benzopyrans as selective estrogen receptor-beta agonists

INVENTOR(S): Dodge, Jeffrey Alan, Indianapolis, IN, UNITED STATES
Krishnan, Venkatesh, Fishers, IN, UNITED STATES
Lugar, Charles Willis, McCordsville, IN, UNITED STATES
Neubauer, Blake Lee, Carmel, IN, UNITED STATES
Norman, Bryan Hurst, Indianapolis, IN, UNITED STATES

Pfeifer, Lance Allen, Indianapolis, IN, UNITED STATES
Richardson, Timothy Ivo, Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004249167	A1	20041209	
APPLICATION INFO.:	US 2004-493092	A1	20040420	(10)
	WO 2002-US33622		20021107	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60332766	20011119
	US 2002-60363622	20020311

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michael J Sayles, Eli Lilly & Company, Patent Division, PO Box 6288, Indianapolis, IN, 46206-6288
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 2943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor β agonists. Such agonists are useful for the treating Estrogen Receptor β mediated diseases such as prostate cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:300069 USPATFULL Full-text
TITLE: Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
INVENTOR(S): Sanders, Bob G., Austin, TX, UNITED STATES
Kline, Kimberly, Austin, TX, UNITED STATES
Hurley, Laurence, Austin, TX, UNITED STATES
Gardner, Robb, Austin, TX, UNITED STATES
Menchaca, Marla, Austin, TX, UNITED STATES
Yu, Weiping, Austin, TX, UNITED STATES
Ramanan, Puthucode N., Austin, TX, UNITED STATES
Liu, Shenquan, Austin, TX, UNITED STATES
Israel, Karen, Austin, TX, UNITED STATES
PATENT ASSIGNEE(S): Research Development Foundation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004235938	A1	20041125	
APPLICATION INFO.:	US 2003-644418	A1	20030820	(10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-502592, filed on 11 Feb 2000, GRANTED, Pat. No. US 6770672 Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, GRANTED, Pat. No. US 6417223

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 2556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:240352 USPATFULL Full-text
TITLE: Polyphenol proteasome inhibitors, synthesis, and methods of use
INVENTOR(S): Dou, Q. Ping, Grosse Pointe, MI, UNITED STATES
Chan, Tak-Hang, Montreal, CANADA
Smith, David M., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004186167	A1	20040923	
APPLICATION INFO.:	US 2004-764728	A1	20040126	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-442213P	20030124	(60)
	US 2003-443554P	20030130	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 32606-6669
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 2140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:192666 USPATFULL Full-text
TITLE: Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof

INVENTOR(S): Sanders, Bob G., Austin, TX, United States
Kline, Kimberly, Austin, TX, United States
Hurley, Laurence, Austin, TX, United States
Gardner, Robb, Austin, TX, United States
Menchaca, Marla, Austin, TX, United States
Yu, Weiping, Austin, TX, United States
Ramanan, Puthucode N., Austin, TX, United States
Liu, Shenquan, Austin, TX, United States
Israel, Karen, Austin, TX, United States
PATENT ASSIGNEE(S): Research Development Foundation, Carson City, NV, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6770672	B1	20040803
APPLICATION INFO.:	US 2000-502592		20000211 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, now patented, Pat. No. US 6417223, issued on 9 Jul 2002

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101543P	19980923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fonda, Kathleen K.
ASSISTANT EXAMINER: Maier, Leigh C.
LEGAL REPRESENTATIVE: Adler, Benjamin Aaron
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 2359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:138645 USPATFULL Full-text
TITLE: Identifying therapeutic compounds based on their physical-chemical properties
INVENTOR(S): Gilat, Sylvain, San Francisco, CA, UNITED STATES
Binyamin, Gary, Palo Alto, CA, UNITED STATES
Miller, Guy, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004105817	A1	20040603
APPLICATION INFO.:	US 2003-696752	A1	20031029 (10)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2002-422727P	20021030 (60)
	US 2003-487734P	20030716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GALILEO PHARMACEUTICALS, INC., (PREVIOUSLY GALILEO LABORATORIES, INC.), 5301 PATRICK HENRY DRIVE, SANTA CLARA, CA, 95954	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	1812	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2004:127448 USPATFULL Full-text		
TITLE:	Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof		
INVENTOR(S):	Sanders, Bob G., Austin, TX, UNITED STATES Kline, Kimberly, Austin, TX, UNITED STATES Yu, Weiping, Austin, TX, UNITED STATES		
PATENT ASSIGNEE(S):	Research Development Foundation (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097431	A1	20040520
APPLICATION INFO.:	US 2003-695275	A1	20031028 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-8066, filed on 5 Nov 2001, GRANTED, Pat. No. US 6703384 Continuation-in-part of Ser. No. US 2000-502592, filed on 11 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, GRANTED, Pat. No. US 6417223		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Benjamin Aaron Adler, Ph.D., J.D., Adler & Associates, 8011 Candle Lane, Houston, TX, 77071	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2605	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an antiproliferative compound having a structural formula ##STR1##

where X and Y independently are oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitrites; R.sup.2 and R.sup.3 are hydrogen or R.sup.4; R.sup.4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R.sup.5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R.sup.6, wherein R.sup.6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2003:268231 USPATFULL Full-text
TITLE:	Substituted benzopyrans as selective estrogen receptor β agonists
INVENTOR(S):	Dodge, Jeffrey Alan, Indianapolis, IN, United States Krishnan, Venkatesh, Fishers, IN, United States Lugar, III, Charles Willis, McCordsville, IN, United States Neubauer, Blake Lee, Carmel, IN, United States
PATENT ASSIGNEE(S):	Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6630508	B1	20031007
APPLICATION INFO.:	US 2003-349521		20030122 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355891P	20020211 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Aulakh, Charanjit S.
LEGAL REPRESENTATIVE:	Sayles, Michael J.
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	1385

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor β agonists. Such agonists are useful for treating Estrogen Receptor β mediated diseases such as prostate cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2002:280579 USPATFULL Full-text
TITLE:	Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
INVENTOR(S):	Sanders, Bob G., Austin, TX, UNITED STATES Kline, Kimberly, Austin, TX, UNITED STATES

Hurley, Laurence, Austin, TX, UNITED STATES
Gardner, Robb, Austin, TX, UNITED STATES
Menchaca, Marla, Austin, TX, UNITED STATES
Yu, Weiping, Austin, TX, UNITED STATES
Ramanan, Puthucode N., Austin, TX, UNITED STATES
Liu, Shenquan, Austin, TX, UNITED STATES
Israel, Karen, Austin, TX, UNITED STATES

PATENT ASSIGNEE(S): Research Development Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002156024	A1	20021024
	US 6645998	B2	20031111
APPLICATION INFO.:	US 2002-122019	A1	20020412 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-404001, filed on 23 Sep 1999, GRANTED, Pat. No. US 6417223

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers and nitriles; R.sup.2 is hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.3 is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.4 is of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; and R.sup.5 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:217302 USPATFULL Full-text
TITLE: Method of suppressing tumor growth with combinations of isoprenoids and statins
INVENTOR(S): Elson, Charles E., Madison, WI, United States
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6441029 B1 20020827
APPLICATION INFO.: US 2000-587737 20000605 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1998-27546, filed on 23 Feb 1998, now patented, Pat. No. US 6133312

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39790P	19970304 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Goldberg, Jerome D.
LEGAL REPRESENTATIVE: Quarles & Brady LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of inhibiting the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:199098 USPATFULL Full-text
TITLE: Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
INVENTOR(S): Sanders, Bob G., Austin, TX, UNITED STATES
Kline, Kimberly, Austin, TX, UNITED STATES
Yu, Weiping, Austin, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107207	A1	20020808
	US 6703384	B2	20040309
APPLICATION INFO.:	US 2001-8066	A1	20011105 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-502592, filed on 11 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-404001, filed on 23 Sep 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 2606
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an antiproliferative compound having a structural formula ##STR1##

where X and Y independently are oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate,

carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitrites; R.sup.2 and R.sup.3 are hydrogen or R.sup.4; R.sup.4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R.sup.5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R.sup.6, wherein R.sup.6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2002:168253 USPATFULL Full-text
TITLE:	Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof
INVENTOR(S):	Sanders, Bob G., Austin, TX, United States Kline, Kimberly, Austin, TX, United States Hurley, Laurence, Austin, TX, United States Gardner, Robb, Austin, TX, United States Menchaca, Marla, Austin, TX, United States Yu, Weiping, Austin, TX, United States Ramanan, Puthucode N., Austin, TX, United States Liu, Shenquan, Austin, TX, United States Israel, Karen, Austin, TX, United States
PATENT ASSIGNEE(S):	Research Development Foundation, Carson City, NV, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6417223	B1	20020709	
APPLICATION INFO.:	US 1999-404001		19990923	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101542P	19980923 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Wilson, James O.
ASSISTANT EXAMINER:	Maier, Leigh C.
LEGAL REPRESENTATIVE:	Adler, Benjamin Aaron
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT:	1959

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an antiproliferative compound having the structural formula ##STR1##

wherein X is oxygen, nitrogen or sulfur; R.sup.1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers and nitriles; R.sup.2 is hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.3 is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide and amine; R.sup.4 is of methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl

carboxamide, benzylester, saccharide and amine; and R.sup.5 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, amide and ester. Also provided is a method for inducing apoptosis in a cell comprising administering a composition comprising a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2000:138398 USPATFULL Full-text		
TITLE:	Method of suppressing tumor growth with combinations of isoprenoids and statins		
INVENTOR(S):	Elson, Charles E., Madison, WI, United States		
PATENT ASSIGNEE(S):	Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6133312		20001017
APPLICATION INFO.:	US 1998-27546		19980223 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 1997-39790P		19970304 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Quarles & Brady LLP		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1104		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of inhibiting the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> **d his**

(FILE 'HOME' ENTERED AT 11:59:27 ON 30 JAN 2007)

FILE 'REGISTRY' ENTERED AT 11:59:45 ON 30 JAN 2007

L1		STRUCTURE UPLOADED
L2	0	S L1
L3	0	S L1 FULL
L4	0	S L1 SSS FULL
L5		STRUCTURE UPLOADED
L6	900	S L5 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:06:59 ON 30 JAN 2007

L7	1190	S L6
L8	1040	S L7 NOT PY>2004
L9	16	S L8 AND "PROSTATE CANCER"
L10	12	S L8 AND "ANDROGEN"

=> **s l8 and "antiandrogen or antiandrogenic"**
L11 0 L8 AND "ANTIANDROGEN OR ANTIANDROGENIC"

=> **s l8 and "androgen antagonist"**
L12 2 L8 AND "ANDROGEN ANTAGONIST"

=> **d l12 1-2 ibib, abs, hitstr**

L12 ANSWER 1 OF 2 MEDLINE on STN
ACCESSION NUMBER: 2003400986 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 12939470
TITLE: Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.
AUTHOR: Thompson Todd A; Wilding George
CORPORATE SOURCE: University of Wisconsin Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin 53792, USA.
SOURCE: Molecular cancer therapeutics, (2003 Aug) Vol. 2, No. 8, pp. 797-803.
Journal code: 101132535. ISSN: 1535-7163.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200406
ENTRY DATE: Entered STN: 27 Aug 2003
Last Updated on STN: 24 Jun 2004
Entered Medline: 21 Jun 2004

AB Antioxidants, such as vitamin E, are being investigated for efficacy in prostate cancer prevention. In this study, we show that the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol (PMCol), has antiandrogen activity in prostate carcinoma cells. In the presence of PMCol, the androgen-stimulated biphasic growth curve of LNCaP human prostate carcinoma cells was shifted to the right. The PMCol-induced growth shift was similar to that produced by treatment with the pure antiandrogen bicalutamide (i.e., Casodex), indicative of androgen receptor (AR) antagonist activity. The concentration of PMCol used was below the concentration required to affect cell growth or viability in the absence of androgen. Using an AR binding competition assay, PMCol was found to be a potent antiandrogen in both LNCaP and LAPC4 cells, with an IC(50) of approximately 10 micro M against 1 nM R1881 (methyltrienolone; a stable, synthetic androgen). Prostate-specific antigen release from LNCaP cells produced by androgen exposure with either 0.05 or 1.0 nM R1881 was inhibited 100% and 80%, respectively, by 30 micro M PMCol. Also, PMCol inhibited androgen-induced promoter activation in both LNCaP and LAPC4 cells. However, PMCol did not affect AR protein levels, suggesting that the inhibitory effects of PMCol on androgenic pathways were not due to decreased expression of the AR. Therefore, growth modulation by the antioxidant moiety of vitamin E in androgen-sensitive prostate carcinoma cells is due, at least in part, to its potent antiandrogenic activity.

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:665773 CAPLUS Full-text
DOCUMENT NUMBER: 140:52950
TITLE: Androgen Antagonist Activity by the Antioxidant Moiety of Vitamin E, 2,2,5,7,8-Pentamethyl-6-chromanol in Human Prostate Carcinoma Cells

AUTHOR(S): Thompson, Todd A.; Wilding, George
CORPORATE SOURCE: University of Wisconsin Comprehensive Cancer Center and University of Wisconsin Department of Medicine, University of Wisconsin-Madison, Madison, WI, 53792, USA
SOURCE: Molecular Cancer Therapeutics (2003), 2(8), 797-803
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Antioxidants, such as vitamin E, are being investigated for efficacy in prostate cancer prevention. In this study, we show that the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol (PMCol), has antiandrogen activity in prostate carcinoma cells. In the presence of PMCol, the androgen-stimulated biphasic growth curve of LNCaP human prostate carcinoma cells was shifted to the right. The PMCol-induced growth shift was similar to that produced by treatment with the pure antiandrogen bicalutamide (i.e., Casodex), indicative of androgen receptor (AR) antagonist activity. The concentration of PMCol used was below the concentration required to affect cell growth or viability in the absence of androgen. Using an AR binding competition assay, PMCol was found to be a potent antiandrogen in both LNCaP and LAPC4 cells, with an IC50 of approx. 10 μM against 1 nM R1881 (methyltrienolone; a stable, synthetic androgen). Prostate-specific antigen release from LNCaP cells produced by androgen exposure with either 0.05 or 1.0 nM R1881 was inhibited 100% and 80%, resp., by 30 μM PMCol. Also, PMCol inhibited androgen-induced promoter activation in both LNCaP and LAPC4 cells. However, PMCol did not affect AR protein levels, suggesting that the inhibitory effects of PMCol on androgenic pathways were not due to decreased expression of the AR. Therefore, growth modulation by the antioxidant moiety of vitamin E in androgen-sensitive prostate carcinoma cells is due, at least in part, to its potent antiandrogenic activity.

IT 950-99-2, 2,2,5,7,8-Pentamethyl-6-chromanol
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells)

RN 950-99-2 CAPLUS
CN 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> **d his**

(FILE 'HOME' ENTERED AT 11:59:27 ON 30 JAN 2007)

```
     FILE 'REGISTRY' ENTERED AT 11:59:45 ON 30 JAN 2007
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              0 S L1 FULL
L4              0 S L1 SSS FULL
L5                STRUCTURE UPLOADED
L6            900 S L5 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:06:59 ON 30 JAN
     2007
L7           1190 S L6
L8           1040 S L7 NOT PY>2004
L9             16 S L8 AND "PROSTATE CANCER"
L10            12 S L8 AND "ANDROGEN"
L11             0 S L8 AND "ANTIANDROGEN OR ANTIANDROGENIC"
L12             2 S L8 AND "ANDROGEN ANTAGONIST"

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   169.17     689.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.90      -3.90

STN INTERNATIONAL LOGOFF AT 12:15:27 ON 30 JAN 2007
```